Previous 10 | Next 10 |
Non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease, is easily the world's largest untapped drug market. NASH drug sales, in fact, could exceed an eye-popping $62 billion as soon as 2028, according to various Wall Street analysts and industry inside...
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Lisa DeFrancesco a...
Over the past years, many companies have struggled to offer the first NASH cure to the market. Billions of investments have been spent on the study and possible treatments of this complex disease. So far, no company has been able to get approval for its drug with NASH indication. But many ...
Truth is a demure lady, much too ladylike to knock you on your head and drag you to her cave. She is there, but people must want her, and seek her out. " - William F. Buckley Jr. Today, we take an in-depth look at a well-known mid-cap biotech stock that has seen significant negative senti...
Atreca (NASDAQ: BCEL ) initiated with Buy rating and $30 (61% upside) price target at Roth Capital. More news on: Atreca, Inc., Constellation Pharmaceuticals, Inc., Ovid Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Our perfect companions never have fewer than four feet. ” - Colette The market got upended yet again on Friday on increasing trade tensions. China escalated the trade war by targeting an additional $75 billion worth of American imports for new tariffs. The administration imme...
If you want big growth from your investments, you have to smart small. That might sound contradictory since most small-cap stocks will never make it to the blue chip level, but small-cap stocks, generally defined as having a market cap between $300 million and $2 billion, give investors the gr...
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating ...
Introduction For two decades, the scientific advance of investigative drug candidates for PBC into clinical development seemed like an illusion. FDA approval of obeticholic acid (i.e. ocaliva) in 2016 as a breakthrough therapeutics developed by Intercept ( ICPT ) for patients with mild PBC...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...